Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

417301

registered interest
date	07/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Reciprocal Arrangements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the independent report entitled Qualitative Assessment of Visitor and Migrant use of the NHS in England: Observations from the Front-Line, which was commissioned by his Department and published on 22 October 2013, what steps he has taken in response to the concerns about the application process for European Health Insurance Cards raised in that report; and when he was first informed about such concerns.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	9201
answer	answer is ministerial correction date of answer 10/09/2015 answer text <p>The Department takes any allegations of fraud and abuse seriously and has been working with the National Health Service on an ongoing basis to detect and tackle any suspected fraud and error since the introduction of the online European Health Insurance Card (EHIC) application system in 2006.</p><p> </p><p> </p><p> </p><p>The Department is tightening up procedures for issuing EHICs and checking EHIC claims to the United Kingdom.</p><p> </p><p> </p><p> </p><p>The Department is already undertaking a major piece of work to examine and identify areas for improvement in all the administrative systems relating to European Economic Area healthcare payments, including the EHIC. The Department expects to complete this work by the end of the year.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 10/09/2015 15:06:35 answering member 1201 label Biography information for Alistair Burt
tabling member	1506 label Biography information for Andrew Gwynne

417302

registered interest
date	07/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Accident and Emergency Departments: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether NHS England will continue to record and monitor weekly A&E performance following the decision to publish only monthly data.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	9200
answer	answer is ministerial correction date of answer 10/09/2015 answer text <p>NHS England, based on the clinical advice of its Medical Director Sir Bruce Keogh, no longer collects weekly data on accident and emergency performance. These data are now collected and published monthly by NHS England.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/09/2015 14:48:10 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

391816

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request that NHS England clarify the mechanisms available for manufacturers of medical technologies to appeal against a negative specialised service commissioning policy decision.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	8282
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>There is no formal appeals process. All stakeholders - including manufacturers, patients and patient groups - are invited to submit their views on proposed commissioning polices via a process of public consultation, the outcome of which is considered by the Clinical Priorities Advisory Group when it meets to form recommendations to NHS England on whether a proposed policy should be commissioned.</p><p> </p><p><strong> </strong></p><p> </p><p>Decisions that are made can be reconsidered at a later date when new evidence is presented.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:00:41 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

391818

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request that NHS England publish the criteria for approving a specialised service commissioning policy.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	8283
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The criteria used for approving specialised service commissioning policy, entitled <em>NHS England’s response to a public consultation &quot;Investing in specialised services&quot;</em> can be found on the NHS England website:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf" target="_blank">http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:22:21 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

391830

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prosthetics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request that NHS England publish a timeline for the re-publication of a commissioning policy on (a) microprocessor knees, (b) multi-articulating prosthetic hands and (c) custom made silicon covers.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	8279
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>NHS England has advised that it has commissioned an independent evidence review in relation to microprocessor knees, multi-articulating prosthetic hands and custom made silicon covers which is expected to be complete by September 2015. A more detailed understanding of next steps including potential timelines will be possible once the evidence review has been considered by NHS England.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:14:54 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

391839

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many (a) new cancer medicines and (b) new indications of existing cancer medicines are expected to be licensed between July 2015 and 31 March 2016.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	8162
answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>There are currently 11 applications for new cancer medicines and 15 applications for new indications for existing cancer medicines under review by the Medicines and Healthcare products Regulatory Agency (MHRA) as part of European Centralised Procedures submitted to the European Medicines Agency (EMA). There is one further application for a new indication for an existing cancer medicine under review by MHRA in an application submitted in the United Kingdom as part of a Mutual Recognition Procedure.</p><p> </p><p> </p><p> </p><p>Under European Centralised Procedures, it takes up to 210 days for an opinion on licensing for new applications and 120 days for an opinion on variation applications for new indications to be given by the scientific committee of the EMA, the Committee for Human Medicinal Products (CHMP), excluding time taken by the Company to provide further information or data to support any questions which may arise during the assessment process. If the assessment concludes that the quality, safety and efficacy are satisfactory and a positive opinion is given by the CHMP, the European Commission will then consider the opinion and decide upon granting or varying a marketing authorisation, valid across the European Community. For a national variation procedure, the same timeline of 120 days, excluding time taken by the Company to provide further information, applies.</p><p> </p><p> </p><p> </p><p>At this time, the MHRA, the UK Government body responsible for medicines regulation in the UK, is unable to provide more precise detail on the timeline for completion of the review of the applications currently with the EMA and MHRA, and it is not possible to predict with certainty what will be licensed between July 2015 and 31 March 2016, nor can any information be provided on applications not yet submitted but which may be approved before 31 March 2016.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 12:35:00 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

391843

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plans for a new system for the reimbursement of cancer drugs to be in place by April 2016 when the current Cancer Drugs Fund is proposed to end.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	8164
answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>NHS England has advised that the Cancer Drugs Fund in its current form is due to operate until 1 April 2016. We understand that NHS England and the National Institute for Health and Care Excellence will shortly be consulting jointly on a proposed new system for commissioning cancer drugs.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 15:14:37 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

390348

registered interest
date	15/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans NHS England has to remove treatments included on the National Cancer Drugs Fund list; and what estimate his Department has made of the number of treatments on the National Cancer Drugs Fund list that are likely to be removed in prioritisation reviews in the next five years.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	7364
answer	answer is ministerial correction date of answer 20/07/2015 answer text <p>NHS England has advised that its Cancer Drugs Fund (CDF) panel expects to hold a meeting on 29-30 July 2015 to prioritise the drugs/indications currently available on the national CDF list.</p><p> </p><p> </p><p> </p><p>The CDF in its current form is due to operate until 1 April 2016 and therefore the revised national CDF list will be operational until at least then.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/07/2015 16:49:07 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

390360

registered interest
date	15/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many cancer treatments have been (a) denied entry to or (b) removed from the Cancer Drugs Fund on cost grounds since January 2015.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	7309
answer	answer is ministerial correction date of answer 20/07/2015 answer text <p>NHS England has advised that no cancer treatments have been removed from or denied entry to the Cancer Drugs Fund (CDF) on cost grounds alone. NHS England’s CDF panel makes its prioritisation decisions based on the national CDF prioritisation tool.</p><p> </p><p> </p><p> </p><p>Since 1 January 2015, 14 drugs and indications have been denied entry to the Fund and 25 drugs have been removed from the Fund. However, four of these removals followed a positive recommendation by the National Institute for Health and Care Excellence which saw those drugs being routinely commissioned by the National Health Service.</p><p> </p><p> </p><p> </p><p>Two drugs have been added for three indications - panitumumab for bowel cancer, ibrutinib for Mantle cell lymphoma and ibrutinib for use in chronic lymphocytic leukaemia.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/07/2015 16:49:49 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

390361

registered interest
date	15/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department will submit a response to NHS England's consultation on the Cancer Drugs Fund Standard Operating Procedures; and if he will make a statement.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	7310
answer	answer is ministerial correction date of answer 20/07/2015 answer text <p>NHS England has responsibility for the operational management of the Cancer Drugs Fund (CDF) and published its <em>Standard Operating Procedures: Guidance to support operation of the CDF in 2015-16</em> on 21 May 2015. This sets out the basis on which the CDF panel will make decisions on which drugs are included within the national CDF list and is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2015/05/sop-delegtd-auth-changes.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2015/05/sop-delegtd-auth-changes.pdf</a></p><p> </p><p> </p><p> </p><p>The Department did not respond to NHS England’s consultation on revised CDF standard operating procedures in Autumn 2014 and has not submitted a response to NHS England’s recent consultation on the Fund’s standard operating procedures which closed on 18 June 2015.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/07/2015 16:43:37 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne